Galectin gets notice of allowance for patent app related to GR-MD-02

• The USPTO issues a notice of allowance to Galectin Therapeutics (GALT +0.8%) for its patent application entitled "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." The patent covers composition and chemical structure claims for the company's lead galectin inhibitor compound GR-MD-02. The patent will be in effect until 2031.